A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Therapy in Patients with Small Cell Lung Cancer

Garst, Jennifer; Herndon, James E.; Shafman, Timothy D.; Campagna, Lara; Blackwell, Susan; Padilla, Karen; Bjurstrom, Toni; Andrews, Carolyn; Maravich-May, Diana; Anderson, Elizabeth; Crawford, Jeffrey

doi:10.2165/00044011-200626050-00003

Clinical Drug Investigation

2006

DOI: 10.2165/00044011-200626050-00003

|View full text |Cite

A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Therapy in Patients with Small Cell Lung Cancer

Jennifer Garst

James E. Herndon

Timothy D. Shafman

et al.

Abstract: The results of this phase I study suggest that a regimen of sequential dose-dense topotecan and carboplatin plus etoposide is feasible, and the preliminary activity observed in patients with SCLC warrants further investigation at a starting dose of topotecan 2.25 mg/m2/day.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer

Garst¹

2006

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

show abstract

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer

Garst¹

2006

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Therapy in Patients with Small Cell Lung Cancer

Abstract: The results of this phase I study suggest that a regimen of sequential dose-dense topotecan and carboplatin plus etoposide is feasible, and the preliminary activity observed in patients with SCLC warrants further investigation at a starting dose of topotecan 2.25 mg/m2/day.

Cited by 1 publication

References 16 publications

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer

Contact Info

Product

Resources

About